Table 1.
Clinical characteristics of patients with acquired resistance to osimertinib by line of therapy
| Clinical characteristics | First-line Osimertinib (%) | Later-line Osimertinib (%) | Total N (%) |
|||
|---|---|---|---|---|---|---|
| Total | 27 | 35 | 62 | |||
| Age | ||||||
| Median (range) | 58 (44–75) | 59 (40–75) | 58 (40–75) | |||
| Sex | ||||||
| Male | 12 (44) | 11 (31) | 23 (37) | |||
| Female | 15 (56) | 24 (69) | 39 (63) | |||
| Smoking | ||||||
| Never-smoker | 17 (63) | 22 (63) | 39 (63) | |||
| Former smoker | 10 (37) | 13 (37) | 23 (37) | |||
| Histology | Before Osi | After Osi | Before Osi | After Osi | Before Osi | After Osi |
| Adenocarcinoma | 24 (89) | 20 (74) | 35 (100) | 28 (80) | 59 (95) | 49 (79) |
| Squamous | 2 (7) | 4 (15) | 0 (0) | 3 (9) | 2 (3) | 6 (10) |
| Neuroendocrine | 0 (0) | 1 (4) | 0 (0) | 2 (6) | 0 (0) | 3 (5) |
| Other | 1 (4) | 2 (7) | 0 (0) | 2 (6) | 1 (2) | 4 (7) |
| EGFR mutation | ||||||
| Exon 19 deletion | 14 (52) | 28 (80) | 42 (68) | |||
| L858R | 11 (41) | 6 (17) | 17 (27) | |||
| T790M | 1 (4) | 32 (91) | 33 (53) | |||
| Other | 2 (7) | 1 (3) | 3 (5) | |||
The demographics, histology, and sensitizing EGFR mutation for the two cohorts and the overall population is shown. Abbreviations: Osi, osimertinib; EGFR, epidermal growth factor receptor.